Dear all,
Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.
Biosimilar insulin trials at Profil
|
 |
Profil is the leading provider of biosimilar insulin trials according to the new EU guidelines on such molecules. Learn more about Profil's offerings in this area. Our automated glucose clamp technology is key to a successful trial.
|
|
|
|
Flow mediated dilatation for measurement of endothelial function
|
 |
This week we will air our live online seminar on flow mediated dilatation to study endothelial function in clincial trials. The live online seminar took place on the 22nd of March. Watch the recording.
|
|
|
|
Studying β-cell function using glucose clamp methods
|
 |
Pancreatic ß-cell function changes in response to pharmacological or life-style interventions. Read about the methods routinely used at Profil to study β-cell function and insulin sensitivity. There a various methods available and the exact research question should ultimately decide which one to use.
|
|
|
|
Profil recently published a study on a soluble glucagon analog
|
 |
Treatment of severe hypoglycemia relies on glucagon formulations which currently require reconstitution before use. This can be a challenge for typically untrained helpers. We recently published a study on a novel soluble and stable glucagon analog. Read the abstract.
|
|
|
|
Meet us at upcoming conferences
|
 |
Are you interested in knowing more about Profil? We attend all major conferences focused on diabetes, so if you are planning to go to any upcoming conference, we would love to schedule a meeting and tell you more about our expertise! |
|
|
We wish you a good week and look forward to the next "Profil World",
Dr Lars Bochmann - Director Scientific Communication, Profil
|
|
